Erbitux Plus Encorafenib Approved for BRAF V600E Mutation-Positive Metastatic Colorectal Cancer
The approval is supported by data from the phase 3 BEACON CRC trial.
Oncology
Tivdak Approved for Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 2 innovaTV 204 trial that evaluated Tivdak as monotherapy in 101 women with recurrent or metastatic cervical cancer.
Cabometyx Approved for Radioactive Iodine-Refractory Differentiated Thyroid Cancer
The approval was based on data from the phase 3 COSMIC-311 study.
Exkivity Approved for EGFR Exon 20 Insertion+ NSCLC
Exkivity (mobocertinib) is approved to treat adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
Brukinsa Approved for Waldenström Macroglobulinemia
The approval was based on data from the phase 3 ASPEN trial.
Keytruda Gets Full Approval for First-Line Advanced Urothelial Carcinoma
The full approval was based on data from the confirmatory phase 3 KEYNOTE-361 trial.
Tecentriq Indication for Triple-Negative Breast Cancer Withdrawn
In 2019, the FDA granted accelerated approval to Tecentriq, a PD-L1 blocking antibody, for unresectable locally advanced or metastatic TNBC.
Tibsovo Approved for IDH1-Mutated Cholangiocarcinoma
The approval was based on data from the double-blind, placebo-controlled ClarIDHy study.
FDA-Approved Ovarian Cancer Treatments
FDA-Approved treatment options for individuals with ovarian cancer including dosing.
FDA-Approved Non-Small Cell Lung Cancer (NSCLC) Treatments
Chemotherapeutic and biologic agents for the treatment of non-small cell lung cancer (NSCLC).
- Loading...
Loading...
Loading... 
Loading...